Breaking News Instant updates and real-time market news.

REGN

Regeneron

$344.48

7.46 (2.21%)

, SNY

Sanofi

$41.66

-0.29 (-0.69%)

09:01
05/07/19
05/07
09:01
05/07/19
09:01

Regeneron and Sanofi announce EC approved new indication for Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Commission, or EC, approved a new indication for Dupixent, or dupilumab, in asthma. Dupixent is now approved in the European Union, or EU, for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, or FeNO, who are inadequately controlled with high dose inhaled corticosteroid, ICS, plus another medicinal product for maintenance treatment.

REGN

Regeneron

$344.48

7.46 (2.21%)

SNY

Sanofi

$41.66

-0.29 (-0.69%)

  • 07

    May

  • 08

    May

  • 13

    May

  • 31

    May

  • 26

    Jun

REGN Regeneron
$344.48

7.46 (2.21%)

04/08/19
PIPR
04/08/19
NO CHANGE
Target $142
PIPR
Overweight
Alnylam alliance with Regeneron a 'clear positive,' says Piper Jaffray
Alnylam Pharmaceuticals (ALNY) today concluded its 2014 RNAi discovery collaboration with Sanofi (SNY) and announced a new five-year RNAi drug discovery alliance with Regeneron Pharmaceuticals (REGN), Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Alnylam will receive $400M in cash and Regeneron will make a $400M equity investment at $90 per Alnylam share, bringing its estimated pro forma cash to $2.3B, adds the analyst. He believes the alliance is a "clear positive for Alnylam "dramatically expanding" its RNAi drug discovery capabilities and strengthening its balance sheet to advance its own orphan disease programs. Tenthoff reiterates an Overweight rating on Alnylam with a $142 price target. The stock in early trading is down 3%, or $2.95, to $89.94.
04/09/19
BMOC
04/09/19
NO CHANGE
Target $119
BMOC
Outperform
Alnylam price target raised to $119 from $106 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam (ALNY) to $119 and kept his Outperform rating after its announced Regeneron (REGN) partnership on ocular / CNS diseases and liver-related diseases. The analyst expects the collaboration to result in favorable economics that also gives Alnylam an opportunity to co-promote its CNS program, but warns that some pressure on the stock is possible since the equity investment component by Regeneron at $90 per share was $3 below Friday's close.
04/09/19
LEER
04/09/19
NO CHANGE
Target $70
LEER
Market Perform
Alnylam price target raised to $70 from $65 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Alnylam (ALNY) to $70 from $65 after the company announced a collaboration with Regeneron (REGN) to develop and commercialize RNAi therapeutics with a focus on CNS and ocular indications, along with liver-directed NASH therapies and cemdisiran in combination with pozelimab. The analyst believes the terms of the deal, which includes a $400M upfront payment and a $400M equity investment in Alnylam at $90/share, are favorable for Alnylam. Foroohar reiterates a Market Perform rating on Alnylam's shares.
04/17/19
JEFF
04/17/19
NO CHANGE
Target $343
JEFF
Hold
Regeneron price target lowered to $343 from $376 at Jefferies
Jefferies analyst Biren Amin lowered his price target for Regeneron Pharmaceuticals (REGN) to $343 from $376 after doctors in his firm's survey viewed Novartis' (NVS) brolucizumab favorably. Retina specialists are particularly eager to prescribe brolucizumab, Amin tells investors in a research note. "Conservatively" incorporating the doctor estimates for brolucizumab uptake cuts revenue for Regeneron's Eylea in wet age-related macular degeneration by 13% over next two years, says the analyst. His revised Eylea estimates are now 4%-7% below consensus for fiscal 2020 through 2023. Amin thinks the Street underestimates the impact of the brolucizumab entry, which he thinks could "replicate events seen when Eylea launched and encroached on Lucentis share." The analyst keeps a Hold rating on Regeneron.
SNY Sanofi
$41.66

-0.29 (-0.69%)

02/07/19
BMOC
02/07/19
NO CHANGE
Target $412
BMOC
Market Perform
Regeneron price target raised to $412 from $403 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Regeneron (REGN) to $412 after its sales and earnings beat in Q4. The analyst cites the combination of Elyea, the "catch-up" payment from Sanofi (SNY), and a lower than expected tax rate. Luchini is keeping his Market Perform rating on the shares, noting that while "Eylea continues to show strength", he is "cautious on the VEGF competitive landscape".
02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).

TODAY'S FREE FLY STORIES

03:20
05/23/19
05/23
03:20
05/23/19
03:20
General news
FX Action: USD-CAD has sprung back above 1.3450 »

FX Action: USD-CAD has…

02:50
05/23/19
05/23
02:50
05/23/19
02:50
General news
FX Update: The main currencies have traded with limited directional bias »

FX Update: The main…

BCYC

Bicycle Therapeutics

$0.00

(0.00%)

21:58
05/22/19
05/22
21:58
05/22/19
21:58
Syndicate
Bicycle Therapeutics 4.333M share IPO priced at $14.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

21:36
05/22/19
05/22
21:36
05/22/19
21:36
Syndicate
IDEAYA Biosciences 5M share IPO priced at $10.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

MDT

Medtronic

$89.02

1.22 (1.39%)

, HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

20:25
05/22/19
05/22
20:25
05/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$89.02

1.22 (1.39%)

HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

BBY

Best Buy

$69.26

-0.68 (-0.97%)

BJ

BJ's Wholesale

$26.50

0.94 (3.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 11

    Jun

  • 20

    Jun

HFC

HollyFrontier

$42.69

-1.45 (-3.29%)

20:19
05/22/19
05/22
20:19
05/22/19
20:19
Periodicals
Breaking Periodicals news story on HollyFrontier »

HollyFrontier to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$33.43

-0.58 (-1.71%)

, MSFT

Microsoft

$127.67

0.77 (0.61%)

20:04
05/22/19
05/22
20:04
05/22/19
20:04
Recommendations
Pluralsight, Microsoft analyst commentary at First Analysis »

Meetings with Pluralsight…

PS

Pluralsight

$33.43

-0.58 (-1.71%)

MSFT

Microsoft

$127.67

0.77 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

GTE

Gran Tierra

$2.09

-0.03 (-1.42%)

19:28
05/22/19
05/22
19:28
05/22/19
19:28
Hot Stocks
Gran Tierra confirms award of 3 Ecuador blocks with 140K acre total area »

Gran Tierra announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$80.47

0.44 (0.55%)

19:10
05/22/19
05/22
19:10
05/22/19
19:10
Hot Stocks
Progressive's Sieger sells 7,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$157.60

1.83 (1.17%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Hot Stocks
Salesforce Ventures launches $125M Europe Trailblazer Fund »

Salesforce announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 06

    Jun

  • 23

    Jun

MRCY

Mercury Systems

$70.96

0.08 (0.11%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Syndicate
Mercury Systems 6M share Secondary priced at $69.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 23

    May

RNG

RingCentral

$122.58

0.14 (0.11%)

18:57
05/22/19
05/22
18:57
05/22/19
18:57
Hot Stocks
RingCentral CEO: We have an all in one solution for business communications »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 13

    Nov

LB

L Brands

$24.29

1.605 (7.08%)

, VIPS

Vipshop

$7.75

0.095 (1.24%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: L…

LB

L Brands

$24.29

1.605 (7.08%)

VIPS

Vipshop

$7.75

0.095 (1.24%)

CPRT

Copart

$64.99

-0.91 (-1.38%)

CTRP

Ctrip

$37.78

-0.09 (-0.24%)

SNPS

Synopsys

$115.10

-0.63 (-0.54%)

AVP

Avon Products

$4.07

0.875 (27.39%)

GILD

Gilead

$67.25

0.73 (1.10%)

IOVA

Iovance Biotherapeutics

$17.71

1.5 (9.25%)

AMGN

Amgen

$173.23

3.61 (2.13%)

NTAP

NetApp

$62.58

-7.43 (-10.61%)

SCVL

Shoe Carnival

$29.65

-2.6 (-8.06%)

HTHT

Huazhu Group

$34.41

-0.47 (-1.35%)

SBLK

Star Bulk Carriers

$8.13

-0.13 (-1.57%)

ONVO

Organovo

$0.78

-0.158 (-16.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

HMC

Honda

$25.54

-0.17 (-0.66%)

, TKTDY

Takata

$0.00

(0.00%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Honda to recall about 19,000 vehicles in the U.S. over faulty inflator kits »

Honda (HMC) will…

HMC

Honda

$25.54

-0.17 (-0.66%)

TKTDY

Takata

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

18:39
05/22/19
05/22
18:39
05/22/19
18:39
Periodicals
Breaking Periodicals news story on Daiichi Sankyo »

Daiichi Sankyo in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SPOT

Spotify

$127.10

-5.06 (-3.83%)

18:27
05/22/19
05/22
18:27
05/22/19
18:27
Periodicals
Spotify resets some users' passwords over 'suspicious activity,' TechCrunch says »

Spotify has informed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXX

Idexx Laboratories

$250.45

1.24 (0.50%)

18:20
05/22/19
05/22
18:20
05/22/19
18:20
Hot Stocks
Idexx Laboratories CEO: We're at the beginning of our runway for growth »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

OMC

Omnicom

$79.79

-0.3 (-0.37%)

18:15
05/22/19
05/22
18:15
05/22/19
18:15
Hot Stocks
Omnicom CEO sells 60.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.74

0.04 (0.11%)

18:12
05/22/19
05/22
18:12
05/22/19
18:12
Hot Stocks
Boston Scientific initiates trial of WATCHMAN FLX appendage closure platform »

Boston Scientific has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 26

    Jun

  • 13

    Nov

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:03
05/22/19
05/22
18:03
05/22/19
18:03
Hot Stocks
Ctrip reports Q1 gross margin 79% vs. 82% a year ago »

Remained consistent with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:02
05/22/19
05/22
18:02
05/22/19
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Earnings
Ctrip reports Q1 adjusted EPS 44c, consensus 24c »

Reports Q1 revenue $1.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CE

Celanese

$100.10

-0.18 (-0.18%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Hot Stocks
Celanese announces acetyls product price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$54.64

-0.25 (-0.46%)

17:57
05/22/19
05/22
17:57
05/22/19
17:57
Hot Stocks
Dentsply Sirona CFO Alexos to leave company in connection with relocation »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

SIM

Grupo Simec

$9.23

(0.00%)

17:55
05/22/19
05/22
17:55
05/22/19
17:55
Hot Stocks
Grupo Simec receives noncompliance notification from NYSE »

Grupo Simec announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.